Bayer presses for legal shield amid Roundup cancer allegations

Bayer has lobbied Congress to advance legislation that could shield the company from billions of dollars in lawsuits related to its weed killer, Roundup. The proposed measure, part of the farm bill, would make it harder for individuals to claim they were not informed about health risks associated with the herbicide. Bayer’s lobbying efforts focus on glyphosate, the active ingredient in Roundup, which some health authorities consider a carcinogen, though the federal government does not.

The transaction aims to strengthen Bayer’s balance sheet and redirect investments to core businesses. Despite a $10 billion settlement in 2020, Bayer faces unresolved claims and continues to fight in court and lobby for legal protections. Bayer’s campaign targets federal legislation to establish uniform pesticide labeling laws, potentially limiting state-level regulations and lawsuits. The outcome of this effort is crucial for Bayer, as it seeks to mitigate financial liabilities from ongoing litigation.